Insider Selling: Moderna, Inc. (NASDAQ:MRNA) Director Sells 15,000 Shares of Stock

Moderna, Inc. (NASDAQ:MRNAGet Free Report) Director Noubar Afeyan sold 15,000 shares of the stock in a transaction on Wednesday, March 27th. The stock was sold at an average price of $109.06, for a total transaction of $1,635,900.00. Following the transaction, the director now directly owns 2,101,931 shares in the company, valued at $229,236,594.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Noubar Afeyan also recently made the following trade(s):

  • On Wednesday, March 20th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $102.39, for a total transaction of $1,535,850.00.
  • On Wednesday, March 13th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $108.54, for a total transaction of $1,628,100.00.

Moderna Stock Performance

NASDAQ MRNA opened at $106.56 on Friday. Moderna, Inc. has a 52-week low of $62.55 and a 52-week high of $163.24. The company has a 50-day simple moving average of $99.07 and a 200 day simple moving average of $93.50. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.36 and a current ratio of 3.42. The company has a market capitalization of $40.80 billion, a PE ratio of -8.59 and a beta of 1.60.

Moderna (NASDAQ:MRNAGet Free Report) last posted its quarterly earnings data on Thursday, February 22nd. The company reported $0.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $1.33. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. The business had revenue of $2.80 billion during the quarter, compared to the consensus estimate of $2.53 billion. During the same quarter last year, the company posted $3.61 earnings per share. The firm’s quarterly revenue was down 44.9% compared to the same quarter last year. On average, research analysts predict that Moderna, Inc. will post -7.48 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. HSBC reaffirmed a “reduce” rating and issued a $86.00 price objective (up from $75.00) on shares of Moderna in a research note on Monday, February 26th. Oppenheimer raised shares of Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 price objective on the stock in a research note on Tuesday, January 2nd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $125.00 price objective on shares of Moderna in a research note on Thursday. Canaccord Genuity Group raised their price objective on shares of Moderna from $82.00 to $91.00 and gave the company a “hold” rating in a research note on Friday, February 23rd. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a research note on Thursday. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and five have issued a buy rating to the stock. According to MarketBeat, Moderna has a consensus rating of “Hold” and a consensus price target of $129.82.

Read Our Latest Analysis on Moderna

Institutional Trading of Moderna

A number of large investors have recently added to or reduced their stakes in the stock. Cim Investment Management Inc. increased its holdings in Moderna by 4.2% during the first quarter. Cim Investment Management Inc. now owns 2,139 shares of the company’s stock worth $329,000 after buying an additional 86 shares during the last quarter. Cetera Advisor Networks LLC increased its stake in shares of Moderna by 0.5% in the fourth quarter. Cetera Advisor Networks LLC now owns 17,195 shares of the company’s stock worth $3,088,000 after purchasing an additional 87 shares in the last quarter. Ancora Advisors LLC increased its stake in shares of Moderna by 41.2% in the first quarter. Ancora Advisors LLC now owns 329 shares of the company’s stock worth $51,000 after purchasing an additional 96 shares in the last quarter. Sunbelt Securities Inc. increased its stake in shares of Moderna by 7.5% in the first quarter. Sunbelt Securities Inc. now owns 1,428 shares of the company’s stock worth $211,000 after purchasing an additional 100 shares in the last quarter. Finally, Allworth Financial LP increased its stake in shares of Moderna by 6.5% in the fourth quarter. Allworth Financial LP now owns 1,660 shares of the company’s stock worth $165,000 after purchasing an additional 101 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

About Moderna

(Get Free Report)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

See Also

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.